PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
In ER+ and HER2- breast cancer(BC) patients for whom BCS is not feasible, we investigate the
rate of BCS can be increased while decreasing unnecessary chemotherapy thru selective
neoadjuvant chemotherapy or neoadjuvant endocrine therapy using tools of nodal status, Ki-67,
and multigene assay(Mammaprint)